Trial Profile
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Dravet syndrome; Lennox-Gastaut syndrome
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors INSYS Therapeutics, Inc
- 04 Dec 2018 Results presented in an INSYS Therapeutics media release.
- 04 Dec 2018 According to an INSYS Therapeutics, Inc media release, data from the study were presented at the 2018 American Epilepsy Society (AES) annual meeting.
- 20 Nov 2018 According to an INSYS Therapeutics, Inc media release, data from the study will be presented at the 2018 American Epilepsy Society (AES) annual meeting.